40 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of potent and orally bioavailable inhibitors of Human Uric Acid Transporter 1 (hURAT1) and binding mode prediction using homology model.
Shanghai Hengrui Pharmaceutical
Morin (3,5,7,2',4'-pentahydroxyflavone) exhibits potent inhibitory actions on urate transport by the human urate anion transporter (hURAT1) expressed in human embryonic kidney cells.
The Chinese University of Hong Kong
Developing potent human uric acid transporter 1 (hURAT1) inhibitors.
University of Colorado Anschutz Medical Campus
Agents for the Treatment of Gout: Current Advances and Future Perspectives.
Shenyang Pharmaceutical University
Discovery and Characterization of Moracin C as an Anti-Gouty Arthritis/Hyperuricemia Candidate by Docking-Based Virtual Screening and Pharmacological Evaluation.
Southern Medical University
Past, present and future of xanthine oxidase inhibitors: design strategies, structural and pharmacological insights, patents and clinical trials.
Guru Nanak Dev University
Discovery of novel benzbromarone analogs with improved pharmacokinetics and benign toxicity profiles as antihyperuricemic agents.
Southern Medical University
Design, synthesis and activity evaluation of novel lesinurad analogues containing thienopyrimidinone or pyridine substructure as human urate transporter 1 inhibitors.
Shandong University
Discovery of Novel Bicyclic Imidazolopyridine-Containing Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Improved Efficacy and Favorable Druggability.
Shandong University
Discovery of novel verinurad analogs as dual inhibitors of URAT1 and GLUT9 with improved Druggability for the treatment of hyperuricemia.
Southern Medical University
Discovery of Dotinurad (FYU-981), a New Phenol Derivative with Highly Potent Uric Acid Lowering Activity.
Fuji Yakuhin
Novel Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Favorable Druggability.
Shandong University
Pharmacological urate-lowering approaches in chronic kidney disease.
West China Hospital of Sichuan University
Synthesis, biological evaluation and 3D-QSAR studies of 1,2,4-triazole-5-substituted carboxylic acid bioisosteres as uric acid transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia associated with gout.
Tianjin Medical University
Synthesis and evaluation of sulfonamide derivatives as potent Human Uric Acid Transporter 1 (hURAT1) inhibitors.
Chinese Academy of Sciences
SERIES OF PIPERIDINE-SUBSTITUTED BENZOIC ACID COMPOUNDS, AND USE THEREOF
Medshine Discovery
Compounds and methods for modulating interleukin-2-inducible t-cell kinase
Corvus Pharmaceuticals
Crystal of DPP-IV long-acting inhibitor and salt
Chia Tai Tianqing Pharmaceutical Group
Chromone containing sulfonamides as potent carbonic anhydrase inhibitors.
Ondokuz Mayis University
Polyphenol fatty acid esters as serine protease inhibitors: a quantum-chemical QSAR analysis.
Slovak University of Technology
Compounds having activating effect on subtypes of peroxisome proliferator-activated receptors and its preparation method and uses
Zhejiang Hisun Pharmaceutical
First-in-Class Chemical Probes against Poly(ADP-ribose) Glycohydrolase (PARG) Inhibit DNA Repair with Differential Pharmacology to Olaparib.
University of Manchester
Small-Molecule Chemical Probe Rescues Cells from Mono-ADP-Ribosyltransferase ARTD10/PARP10-Induced Apoptosis and Sensitizes Cancer Cells to DNA Damage.
University of Oulu
Development of 2-(Substituted Benzylamino)-4-Methyl-1, 3-Thiazole-5-Carboxylic Acid Derivatives as Xanthine Oxidase Inhibitors and Free Radical Scavengers.
Jamia Hamdard
Non-ATP dependent inhibitors of extracellular signal-regulated kinase (ERK)
University of Maryland, Baltimore
Benzimidazole derivatives as new a-glucosidase inhibitors and in silico studies.
Universiti Teknologi Mara (Uitm)
In vitro binding properties in rat brain of [3H]Ro 25-6981, a potent and selective antagonist of NMDA receptors containing NR2B subunits.
F. Hoffmann-La Roche
A binding site model and structure-activity relationships for the rat A3 adenosine receptor.
National Institute of Diabetes, Digestive and Kidney Diseases